BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon: An Aggressive Adenocarcinoma With Poor Survival, Mucinous Differentiation, and Adverse Morphologic Features
暂无分享,去创建一个
Albert C. Koong | Daniel T. Chang | Raymond R. Balise | Lisa Ma | R. Pai | A. Koong | D. Arber | R. Tubbs | D. Chang | R. Balise | P. Jayachandran | Reetesh K. Pai | Raymond R. Tubbs | Rish K. Pai | Lisa Ma | Priya Jayachandran | Shirley Kwok | Daniel A. Arber | Bonnie Shadrach | Shirley Kwok | R. Pai | B. Shadrach
[1] S. Finkelstein,et al. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K‐ras‐2 mutation type , 1993, Cancer.
[2] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Ryan,et al. Detection of mutated K12-ras in histologically negative lymph nodes as an indicator of poor prognosis in stage II colorectal cancer. , 2001, Clinical colorectal cancer.
[4] Shuji Ogino,et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.
[5] E. Oevermann,et al. Ordinary colorectal adenocarcinoma vs. primary colorectal signet-ring cell carcinoma: study matched for age, gender, grade, and stage. , 1999, Diseases of the colon and rectum.
[6] C. Ko,et al. A 10-Year Outcomes Evaluation of Mucinous and Signet-Ring Cell Carcinoma of the Colon and Rectum , 2005, Diseases of the colon and rectum.
[7] S. Kakar,et al. Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival , 2004, Modern Pathology.
[8] S. Kakar,et al. Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability. , 2008, Archives of pathology & laboratory medicine.
[9] Seta Shahin,et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Seonwoo Kim,et al. Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma , 2008, Modern Pathology.
[11] J. Barrett,et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] K. Cleary,et al. Mucinous carcinomas of the colon and rectum. An analysis of 62 stage B and C lesions. , 1991, Archives of pathology & laboratory medicine.
[13] D. Rakheja,et al. Diagnostic Utility of SALL4 in Extragonadal Yolk Sac Tumors: An Immunohistochemical Study of 59 Cases With Comparison to Placental-like Alkaline Phosphatase, Alpha-fetoprotein, and Glypican-3 , 2009, The American journal of surgical pathology.
[14] G. Miller. Carcinoma of the Colon and Rectum. , 1942, Canadian Medical Association journal.
[15] A. Duval,et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. , 2002, Gastroenterology.
[16] F. Consorti,et al. Prognostic significance of mucinous carcinoma of colon and rectum: A prospective case‐control study , 2000, Journal of surgical oncology.
[17] E. E. Gresch. Genetic Alterations During Colorectal-Tumor Development , 1989 .
[18] G. Deng,et al. BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer , 2004, Clinical Cancer Research.
[19] M. Leppert,et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[20] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] T. Nishida,et al. Primary colorectal signet-ring cell carcinoma: Clinicopathological features and postoperative survival , 2010, Surgery Today.
[22] S. Kakar,et al. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non‐mucinous colorectal cancer , 2006, International journal of cancer.
[23] J. Meyer,et al. Mucinous component in colorectal carcinoma—prognostic significance: A study in a south Indian population , 1992, Journal of surgical oncology.
[24] D. Schaid,et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. , 2003, Cancer research.
[25] D. Symonds,et al. Mucinous carcinoma of the colon and rectum , 1976, Cancer.
[26] J. Ray,et al. Mucinous carcinoma—Just another colon cancer? , 1993, Diseases of the colon and rectum.
[27] Y. Hazewinkel. Serrated polyps of the colon and rectum , 2014 .
[28] J. Guillem,et al. Signet-ring cell carcinoma of the colon and rectum: a matched control study. , 1998, Diseases of the colon and rectum.
[29] H. Appelman,et al. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[30] J. O’Sullivan,et al. Tumor Budding is a Strong and Reproducible Prognostic Marker in T3N0 Colorectal Cancer , 2009, The American journal of surgical pathology.
[31] J. Meyerhardt,et al. KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803 , 2009, Clinical Cancer Research.
[32] R. Houlston,et al. Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Sabine Tejpar,et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] G. Lapertosa,et al. Primary mucinous adenocarcinomas and signet-ring cell carcinomas of colon and rectum. , 1994, Oncology.
[35] M. Kloor,et al. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. , 2008, Gastroenterology.
[36] Norman Wolmark,et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] B. Vogelstein,et al. Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.
[38] Larissa V Furtado,et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer , 2011, Genes, chromosomes & cancer.
[39] D. Kerr,et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] T. Sugai,et al. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas. , 2006, The Journal of molecular diagnostics : JMD.
[41] R. Wolff,et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.
[42] P. Laurent-Puig,et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. , 2008, Cancer research.
[43] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[44] E. Oevermann,et al. Ordinary colorectal adenocarcinomavs. primary colorectal signet-ring cell carcinoma , 1999 .
[45] T. Smyrk,et al. Tumor‐infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma , 2001, Cancer.
[46] Yuri E Nikiforov,et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.
[47] J. Hopper,et al. Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[48] J. Jass,et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion’ pathway to colorectal cancer , 2006, Histopathology.
[49] S. Kakar,et al. Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. , 2008, European journal of cancer.
[50] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[51] Appelman Hd,et al. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. , 1990 .
[52] O. Lozano,et al. Clinical, histopathological, cytogenetic and prognostic differences between mucinous and nonmucinous colorectal adenocarcinomas. , 1998, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[53] L. Messerini,et al. Prognostic significance of microsatellite instability in sporadic mucinous colorectal cancers. , 1999, Human pathology.